We collect and analyze sentiment surrounding JNJ stock to help you make informed investment decisions.
Published on October 2, 2025
Johnson & Johnson continues to lead the way in the healthcare industry with its innovative solutions....
Published on August 10, 2025
Johnson & Johnson, a global healthcare company, has recently been in the spotlight due to controversies surrounding their talc products. Despite this setback, investors are keeping a close eye on the company's new medical innovations, which could pot...
Published on July 14, 2025
Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA. This move is expected to bring significant momentum to the company's stock,...
Published on May 25, 2025
Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....
Published on March 21, 2025
Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....
Published on March 20, 2025
Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....
Published on March 19, 2025
Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....
Published on March 18, 2025
Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group. The company aims to enhance its innovation and research in the field of neurovascular technologies and improve...
Published on March 14, 2025
Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD). IBD is a chronic condition that affects millions of people worldwide and can lead to severe sympt...
Published on February 28, 2025
Johnson & Johnson (JNJ) has shown an impressive 8....
Published on February 26, 2025
Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives. The company's commitment to improving patient ...
Published on February 18, 2025
According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....
Published on February 16, 2025
According to reports, pharmaceutical giant Johnson & Johnson is looking to sell its stroke care business, Cerenovus, for a staggering $1 billion. The company is said to be focusing on its core business areas and streamlining its operations. Cerenovus...
Published on February 14, 2025
Johnson & Johnson, the multinational pharmaceutical company, is reportedly looking to sell its Cerenovus stroke care business for a sum of $1 billion. The decision comes as part of the company's strategy to streamline its portfolio and focus on its c...
Published on February 4, 2025
Johnson & Johnson, the renowned healthcare company, is under scrutiny for alleged misconduct and product safety issues....
Published on January 31, 2025
Johnson & Johnson (JNJ) recently reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations. The company's revenue increased by 10% compared to the previous year, driven by strong sales in its pharmaceutical a...
Published on January 28, 2025
Johnson & Johnson (JNJ) has released its highly anticipated earnings report for the fourth quarter and full-year of 2024....
Published on January 15, 2025
In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion. This acquisition marks a significant expansion f...
Published on January 14, 2025
Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14.6 billion, marks a significant move for J&J into the field of neurology. The c...
Published on January 13, 2025
In a recent development, pharmaceutical giant Johnson & Johnson (JNJ) announced that its lung cancer drug has shown promising results in extending the survival rates of patients. The drug, which is currently undergoing clinical trials, has demonstrat...
Published on January 11, 2025
Johnson & Johnson (JNJ) has announced that its lung cancer drug has shown promising results in extending patient survival....
Published on January 9, 2025
Johnson & Johnson announced today that its revolutionary lung cancer drug, known as Varipulse PFA, has significantly extended the survival of patients in a recent clinical trial. The study, conducted on a large patient population, showed a clear ...
Published on January 8, 2025
Johnson & Johnson (JNJ) announced its quarterly earnings today, showcasing impressive growth and beating analysts' expectations....
Published on January 6, 2025
Johnson & Johnson (JNJ) has recently declared a dividend payout to its shareholders....
Published on January 5, 2025
Johnson & Johnson, a multinational pharmaceutical company, recently declared its quarterly dividend and reported a decline in short interest. The company's dividend reflects its commitment to providing returns to its shareholders. Additionally, the d...